drugset / Trial / NCT03530696
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a single arm, phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival in patients with metastatic HER2 positive breast cancer. All patients will be treated with T-DM1 with palbociclib.
Timeline
- Start
- 2018-12-06
- Primary completion
- 2022-12-22
- Completion
- 2022-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |